Sciences de la vie - réglementation

eAlerts Récentes

•  

  10/09/2024

  Chine

  China’s opens its healthcare sector to more foreign investment

  On 8 September 2024, the China’s Ministry of Commerce (MOFCOM), the National Health Commission (NHC) and the National Medical Products Administration (NMPA) issued a joint Circular on the pilot programmes to further open the republic’s healthcare sector to foreign investors. The Circular outlines two major initiatives: the establishment of wholly foreign-owned hospitals in select regions, including Beijing and Shanghai, and the engagement of foreign-invested enterprises (FIEs) in biotechnology within designated free trade zones (FTZs).Key points of the Circular1. Biotechnology development...

  Lire la suite
•  

  05/09/2024

  Chine

  China enters new regulatory era with release of first draft Medical Devices Administration Law for Public Comment

  On 28 August 2024, China’s National Medical Products Administration (NMPA) released the draft of the Medical Devices Administration Law of the People's Republic of China for public comment with the deadline for feedback set for 28 September 2024.Unlike pharmaceutical products, for over two decades medical devices have not been governed by a national-level law from the National People's Congress, such as the Drug Administration Law, but by an administrative regulation, the Regulation on the Supervision and Administration of Medical Devices (i.e. "Medical Device Regulation"), and various separate...

  Lire la suite
•  

  02/09/2024

  Ukraine

  Ukraine tightens rules on labelling medicines

  On 21 August 2024, the Parliament of Ukraine adopted amendments to the Law on Medicinal Products as a part of an effort to align Ukrainian legislation with EU regulations, particularly Article 54 of Directive 2001/83/EC. These Amendments, however, introduce stricter rules than the EU legislation.Key provisions of the Amendments:1.    Prohibition on non-compliant labelling:The Amendments strictly prohibit the inclusion of any advertising information or references to entities other than the Marketing Authorisation Holder (MAH) or the manufacturer on the packaging of medicinal...

  Lire la suite
•  

  29/08/2024

  Ukraine

  Ukraine to Allow Limited Parallel Import of Medicines from 2025

  On 27 July 2024 a Law of Ukraine On Amendments to Certain Laws of Ukraine Concerning Parallel Import of Medicinal Products (the “Law”) came into force. The Law legalises limited parallel import regime for medicinal products as of 1 January 2025.The Law will bring the following key changes: From 1 January 2025, the parallel import of medicines into Ukraine will be lawful. At first, it will be possible to import medicines into Ukraine from EU countries, Iceland, Liechtenstein, and Norway only.It will be allowed to import medicines identical or similar to those registered in...

  Lire la suite
•  

  15/08/2024

  United Kingdom

  Labour’s proposal to introduce VAT on private school fees – what are the potential implications?

  A key tax plan of the Labour administration was to impose VAT on private school fees.  Now that the 2024 General Election is behind us and the Labour government are starting to settle into their tenure, what do we know about the proposal and how it will affect the various stakeholders? What are the proposed changes?Labour intends to introduce 20% VAT on education, including vocational training, and boarding services which are provided by private schools from 1 January 2025.  Private schools’ eligibility for charitable rates relief will also be removed. The proposed VAT...

  Lire la suite
•  

  14/08/2024

  Chine

  Draft anti-monopoly guidelines in the pharma sector released by China SAMR

  On 9 August 2024, China’s State Administration for Market Regulation (SAMR) released a draft of the Antimonopoly Guidelines in the Field of Pharmaceuticals for public comments. These Guidelines are designed to provide clearer guidance on antitrust enforcement and compliance for operators across the entire pharmaceutical industry.Key elements of the Guidelines1. Expanded scope of applicationThe Guidelines expand and refine the scope of antitrust regulation within the pharmaceutical sector, building on the Anti-monopoly Law of the People's Republic of China (AML) and the previously issued Antitrust...

  Lire la suite